Analysts’ Viewpoint
The escalating global occurrence of pneumonia, especially affecting vulnerable demographics such as children and the elderly is a key factor fueling the pneumonia therapeutics market size. Increase in awareness of environmental risk factors, including air pollution and second-hand smoke, heightens the demand for advanced therapeutic solutions.
Research and development advancements, resulting in innovative drug formulations and treatment methods are offering lucrative opportunities for market expansion. Pharmaceutical companies and researchers are compelled to develop targeted and more effective pneumonia therapeutics to combat the intricate nature of respiratory infections.
Market growth is further fueled by a worldwide commitment to addressing infectious diseases, alongside rise in healthcare expenditure and substantial investments in pharmaceutical research. The industry continues to remains receptive to ongoing developments and advancements in pneumonia therapeutics.
Pneumonia therapeutics comprises pharmaceuticals used to treat respiratory infections, including pneumonia. Pneumonia is a common respiratory disorder with a large worldwide disease burden. The market is focused on discovering novel therapeutic solutions to battle this infectious disease.
The pneumonia therapeutics market responds dynamically to the evolving nature of pneumonia-causing pathogens, emphasizing the continuous adoption of therapeutic strategies to meet these challenges.
The most recent updates in pneumonia treatments include constant research and development efforts to create novel medications and treatment techniques. Pharmaceutical companies are aggressively developing therapeutic solutions to improve the management and treatment of pneumonia, underscoring the industry's vital role in tackling respiratory health issues.
As the industry evolves, there is a constant emphasis on developing effective and tailored medicines to fulfill the increasing need for pneumonia treatment.
Pneumonia remains a significant global health challenge, with a substantial number of cases reported annually. The World Health Organization (WHO) identifies pneumonia as a major contributor to the global disease burden, particularly impacting vulnerable populations including children and the elderly.
According to the Global Burden of Disease Study in 2019, pneumonia was responsible for approximately 2.5 million deaths worldwide. The urgency for effective therapeutic interventions is underscored by the surge in incidence of pneumonia in both community and hospital settings.
WHO reports that pneumonia claims the lives of more than 700,000 children under the age of five each year, totaling around 2,000 deaths daily, including approximately 190,000 newborns. Nearly all of these deaths are preventable. Globally, there are over 1,400 cases of pneumonia per 100,000 children, or 1 case per 71 children annually, with the highest incidence in South Asia (2,500 cases per 100,000 children) and West and Central Africa.
As the prevalence of pneumonia continues to rise, pharmaceutical companies and researchers are spurred to develop innovative drugs and treatment approaches to address this respiratory infection.
The increase in demand for pneumonia therapeutics aligns with the growth in global burden of pneumonia, and emphasizes the crucial role of the pharmaceutical industry in finding solutions to combat this infectious disease, consequently boosting the pneumonia therapeutics market revenue.
Air pollution, often containing particulate matter and harmful pollutants, poses a threat to respiratory health by compromising the immune system and increasing vulnerability to respiratory infections, including pneumonia. Second-hand smoke, recognized as a significant risk factor for pneumonia, particularly in children, has been linked to various adverse respiratory outcomes.
According to the Centers for Disease Control and Prevention (CDC), children exposed to second-hand smoke face an elevated risk of acute respiratory infections such as pneumonia, bronchitis, middle ear disease, more severe asthma, respiratory symptoms, and slowed lung growth.
The CDC also highlights that 21% of lower respiratory infections (LRI) in children are attributed to exposure to household air pollution, contributing to 44% of all pneumonia deaths in children under five years old. Furthermore, household air pollution is a risk factor for acute lower respiratory infections in adults, accounting for 22% of all adult pneumonia-related deaths.
The detrimental impact of second-hand smoke is particularly pronounced in young children, leading to a significant number of lower respiratory tract infections and hospitalizations annually.
The heightened awareness of the interconnectedness between environmental factors, respiratory health, and pneumonia risk emphasizes the importance of therapeutic interventions to effectively manage and treat pneumonia, thus driving the pneumonia therapeutics market growth.
The pneumonia therapeutics market segmentation in terms of type is classified into bacterial pneumonia, viral pneumonia, and fungal pneumonia.
Bacterial pneumonia has emerged as a significant segment within the pneumonia therapeutics market, primarily due to the prevalence of respiratory infections caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae.
This form of pneumonia is recognized for its widespread occurrence and potential severity, especially affecting vulnerable populations such as the elderly and individuals with compromised immune systems. Characterized by a rapid onset, bacterial pneumonia poses the risk of severe complications if not promptly addressed.
Antibiotics, encompassing macrolides, fluoroquinolones, and beta-lactams, are frequently prescribed to combat bacterial infections, emphasizing their crucial role in the management of bacterial pneumonia.
In terms of drug class, the market has been divided into antibiotics, antiviral drugs, antifungal drugs, corticosteroids, and others.
The pneumonia therapeutics market analysis indicates that antibiotics dominate a significant portion of the market. Antibiotics have been the primary treatment for bacterial pneumonia, the most prevalent type, for many years. Their effectiveness in specifically targeting and eliminating bacteria is crucial in alleviating symptoms and saving lives.
With a broad range of antibiotics available, tailored to various bacterial strains and patient characteristics, treatment approaches can be individualized, and made based on resistance patterns. The extensive experience of healthcare professionals in prescribing and administering antibiotics has resulted in well-established treatment protocols, fostering a sense of confidence and familiarity with their use in managing bacterial pneumonia.
As per the latest pneumonia therapeutics market forecast, North America has a significant share of the landscape, attributed to its well-equipped hospitals & clinics that offer diverse diagnostic and treatment options. This infrastructure supports early diagnosis and accessibility to various pneumonia therapeutics.
Notably, the United States outpaces other regions in healthcare spending per capita, enhancing affordability for novel and costly drugs. The presence of leading pharmaceutical companies backed by substantial research and development budgets, further fuels innovation and the creation of new pneumonia drugs in North America.
Strong focus on advancing research and development in the pharmaceutical sector, results in the development of cutting-edge treatments for pneumonia in Europe, enabling a steady pneumonia therapeutics market share. The region benefits from robust regulatory frameworks and healthcare policies that support market development.
The Asia Pacific region is witnessing a surge in number of elderly individuals who are more vulnerable to pneumonia due to weakened immune systems, thereby broadening the potential patient base. High population density, rapid urbanization, and lifestyle changes, fuel market progress in the region.
Rapid economic growth in many Asia Pacific countries has resulted in higher healthcare spending and improved affordability of pneumonia therapeutics, encompassing antibiotics, vaccines, and newer medications.
The global pneumonia therapeutics market is fragmented with the presence of several players. AstraZeneca, Novartis AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, Lupin Pharmaceuticals, Inc., Sumitomo Pharma Co., Ltd., and Wockhardt Ltd. are the key pneumonia therapeutics industry manufacturers.
The report highlights these companies in terms of parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 3.0 Bn |
| Forecast Value in 2031 | More than US$ 5.7 Bn |
| CAGR | 7.3% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 3.0 Bn in 2022
It is projected to reach more than US$ 5.7 Bn by 2031
The CAGR is anticipated to be 7.3% from 2023 to 2031
North America is expected to account for largest share from 2023 to 2031
AstraZeneca, Novartis AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, Lupin Pharmaceuticals, Inc., Innoviva, Inc., Sumitomo Pharma Co., Ltd., and Wockhardt
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Pneumonia Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pneumonia Therapeutics Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events
5.2. Regulatory Scenario
5.3. Disease Incidence & Prevalence Rate by Region/globally
5.4. COVID-19 Impact Analysis
6. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2017-2031
6.3.1. Bacterial Pneumonia
6.3.2. Viral Pneumonia
6.3.3. Fungal Pneumonia
6.4. Market Attractiveness By Type
7. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Age Group
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Age Group, 2017-2031
7.3.1. Children
7.3.2. Adult
7.3.3. Geriatric
7.4. Market Attractiveness By Age Group
8. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Route of Administration, 2017-2031
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Others
8.4. Market Attractiveness By Route of Administration
9. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Drug Class
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Drug Class, 2017-2031
9.3.1. Antibiotics
9.3.2. Antiviral Drugs
9.3.3. Antifungal Drugs
9.3.4. Corticosteroids
9.3.5. Others (NSAIDs, Cough suppressant, etc.)
9.4. Market Attractiveness By Drug Class
10. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Distribution Channel, 2017-2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness By Distribution Channel
11. Global Pneumonia Therapeutics Market Analysis and Forecasts, By Region
11.1. Key Findings
11.2. Market Value Forecast By Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness By Country/Region
12. North America Pneumonia Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type, 2017-2031
12.2.1. Bacterial Pneumonia
12.2.2. Viral Pneumonia
12.2.3. Fungal Pneumonia
12.3. Market Value Forecast By Age Group, 2017-2031
12.3.1. Children
12.3.2. Adult
12.3.3. Geriatric
12.4. Market Value Forecast By Route of Administration, 2017-2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Others
12.5. Market Value Forecast By Drug Class, 2017-2031
12.5.1. Antibiotics
12.5.2. Antiviral Drugs
12.5.3. Antifungal Drugs
12.5.4. Corticosteroids
12.5.5. Others (NSAIDs, Cough suppressant, etc.)
12.6. Market Value Forecast By Distribution Channel, 2017-2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast By Country, 2017-2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Type
12.8.2. By Age Group
12.8.3. By Route of Administration
12.8.4. By Drug Class
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Pneumonia Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type, 2017-2031
13.2.1. Bacterial Pneumonia
13.2.2. Viral Pneumonia
13.2.3. Fungal Pneumonia
13.3. Market Value Forecast By Age Group, 2017-2031
13.3.1. Children
13.3.2. Adult
13.3.3. Geriatric
13.4. Market Value Forecast By Route of Administration, 2017-2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Others
13.5. Market Value Forecast By Drug Class, 2017-2031
13.5.1. Antibiotics
13.5.2. Antiviral Drugs
13.5.3. Antifungal Drugs
13.5.4. Corticosteroids
13.5.5. Others (NSAIDs, Cough suppressant, etc.)
13.6. Market Value Forecast By Distribution Channel, 2017-2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast By Country, 2017-2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Type
13.8.2. By Age Group
13.8.3. By Route of Administration
13.8.4. By Drug Class
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Pneumonia Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type, 2017-2031
14.2.1. Bacterial Pneumonia
14.2.2. Viral Pneumonia
14.2.3. Fungal Pneumonia
14.3. Market Value Forecast By Age Group, 2017-2031
14.3.1. Children
14.3.2. Adult
14.3.3. Geriatric
14.4. Market Value Forecast By Route of Administration, 2017-2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Others
14.5. Market Value Forecast By Drug Class, 2017-2031
14.5.1. Antibiotics
14.5.2. Antiviral Drugs
14.5.3. Antifungal Drugs
14.5.4. Corticosteroids
14.5.5. Others (NSAIDs, Cough suppressant, etc.)
14.6. Market Value Forecast By Distribution Channel, 2017-2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast By Country/Sub-region, 2017-2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of APAC
14.8. Market Attractiveness Analysis
14.8.1. By Type
14.8.2. By Age Group
14.8.3. By Route of Administration
14.8.4. By Drug Class
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Pneumonia Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Type, 2017-2031
15.2.1. Bacterial Pneumonia
15.2.2. Viral Pneumonia
15.2.3. Fungal Pneumonia
15.3. Market Value Forecast By Age Group, 2017-2031
15.3.1. Children
15.3.2. Adult
15.3.3. Geriatric
15.4. Market Value Forecast By Route of Administration, 2017-2031
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Others
15.5. Market Value Forecast By Drug Class, 2017-2031
15.5.1. Antibiotics
15.5.2. Antiviral Drugs
15.5.3. Antifungal Drugs
15.5.4. Corticosteroids
15.5.5. Others (NSAIDs, Cough suppressant, etc.)
15.6. Market Value Forecast By Distribution Channel, 2017-2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast By Country/Sub-region, 2017-2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of LATAM
15.8. Market Attractiveness Analysis
15.8.1. By Type
15.8.2. By Age Group
15.8.3. By Route of Administration
15.8.4. By Drug Class
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Pneumonia Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Type, 2017-2031
16.2.1. Bacterial Pneumonia
16.2.2. Viral Pneumonia
16.2.3. Fungal Pneumonia
16.3. Market Value Forecast By Age Group, 2017-2031
16.3.1. Children
16.3.2. Adult
16.3.3. Geriatric
16.4. Market Value Forecast By Route of Administration, 2017-2031
16.4.1. Oral
16.4.2. Parenteral
16.4.3. Others
16.5. Market Value Forecast By Drug Class, 2017-2031
16.5.1. Antibiotics
16.5.2. Antiviral Drugs
16.5.3. Antifungal Drugs
16.5.4. Corticosteroids
16.5.5. Others (NSAIDs, Cough suppressant, etc.)
16.6. Market Value Forecast By Distribution Channel, 2017-2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast By Country/Sub-region, 2017-2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of MEA
16.8. Market Attractiveness Analysis
16.8.1. By Type
16.8.2. By Age Group
16.8.3. By Route of Administration
16.8.4. By Drug Class
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2022)
17.3. Company Profiles
17.3.1. AstraZeneca
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. Novartis AG
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. AbbVie Inc.
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. Teva Pharmaceutical Industries Ltd.
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Sumitomo Pharma Co., Ltd.
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. Pfizer Inc.
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. Sanofi
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. Lupin Pharmaceuticals, Inc.
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Wockhardt Ltd.
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. Innoviva, Inc.
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments
List of Tables
Table 01: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 03: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
Table 04: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 05: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 06: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 07: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 08: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 09: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
Table 10: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 11: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 12: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 13: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
Table 14: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 15: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 16: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 18: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 19: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
Table 20: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 21: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 22: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 23: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 24: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 25: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
Table 26: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 27: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 28: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 29: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 30: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 31: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Age Group, 2017-2031
Table 32: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 33: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 34: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
List of Figures
Figure 01: Global Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
Figure 03: Global Pneumonia Therapeutics Market Value Share Analysis, by Bacterial pneumonia, 2022-2031
Figure 04: Global Pneumonia Therapeutics Market Value Share Analysis, by Viral Pneumonia, 2022-2031
Figure 05: Global Pneumonia Therapeutics Market Value Share Analysis, by Fungal pneumonia, 2022-2031
Figure 06: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
Figure 07: Global Pneumonia Therapeutics Market Value Share Analysis, by Drug Class 2022-2031
Figure 08: Global Pneumonia Therapeutics Market Value Share Analysis, by Antibiotics, 2022-2031
Figure 09: Global Pneumonia Therapeutics Market Value Share Analysis, by Antiviral Drugs, 2022-2031
Figure 10: Global Pneumonia Therapeutics Market Value Share Analysis, by Antifungal Drugs, 2022-2031
Figure 11: Global Pneumonia Therapeutics Market Value Share Analysis, by Corticosteroids, 2022-2031
Figure 12: Global Pneumonia Therapeutics Market Value Share Analysis, by Others, 2022-2031
Figure 13: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 14: Global Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
Figure 15: Global Pneumonia Therapeutics Market Value Share Analysis, by Children, 2022-2031
Figure 16: Global Pneumonia Therapeutics Market Value Share Analysis, by Adults, 2022-2031
Figure 17: Global Pneumonia Therapeutics Market Value Share Analysis, by Geriatric, 2022-2031
Figure 18: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
Figure 19: Global Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 20: Global Pneumonia Therapeutics Market Value Share Analysis, by Oral, 2022-2031
Figure 21: Global Pneumonia Therapeutics Market Value Share Analysis, by Parenteral, 2022-2031
Figure 22: Global Pneumonia Therapeutics Market Value Share Analysis, by Others, 2022-2031
Figure 23: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 24: Global Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 25: Global Pneumonia Therapeutics Market Value Share Analysis, by Hospital Pharmacies, 2022-2031
Figure 26: Global Pneumonia Therapeutics Market Value Share Analysis, by Retail Pharmacies, 2022-2031
Figure 27: Global Pneumonia Therapeutics Market Value Share Analysis, by Online Pharmacies, 2022-2031
Figure 28: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 29: Global Pneumonia Therapeutics Market Value Share Analysis, by Region, 2022-2031
Figure 30: Global Pneumonia Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
Figure 31: North America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 32: North America Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
Figure 33: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
Figure 34: North America Pneumonia Therapeutics Market Value Share Analysis, by Drug Class, 2022-2031
Figure 35: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 36: North America Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
Figure 37: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
Figure 38: North America Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 39: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 40: North America Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 41: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 42: North America Pneumonia Therapeutics Market Value Share Analysis, by Country, 2022-2031
Figure 43: North America Pneumonia Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 44: Europe Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 45: Europe Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
Figure 46: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
Figure 47: Europe Pneumonia Therapeutics Market Value Share Analysis, by Drug Class, 2022-2031
Figure 48: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 49: Europe Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
Figure 50: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
Figure 51: Europe Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 52: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 53: Europe Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 54: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 55: Europe Pneumonia Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 56: Europe Pneumonia Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 57: Asia Pacific Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 58: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
Figure 59: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
Figure 60: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Drug Class 2022-2031
Figure 61: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 62: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
Figure 63: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
Figure 64: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 65: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 66: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 67: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 68: Asia Pacific Pneumonia Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 69: Asia Pacific Pneumonia Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 70: Latin America Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 71: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
Figure 72: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
Figure 73: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Drug Class, 2022-2031
Figure 74: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 75: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
Figure 76: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
Figure 77: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 78: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 79: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 80: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 81: Latin America Pneumonia Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 82: Latin America Pneumonia Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 83: Middle East & Africa Pneumonia Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 84: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Type, 2022-2031
Figure 85: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Type, 2023-2031
Figure 86: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Drug Class, 2022-2031
Figure 87: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 88: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Age Group, 2022-2031
Figure 89: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Age Group, 2023-2031
Figure 90: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Route of Administration, 2022-2031
Figure 91: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 92: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 93: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 94: Middle East & Africa Pneumonia Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 95: Middle East & Africa Pneumonia Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 96: Global Pneumonia Therapeutics Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pneumonia Therapeutics Market
*86 figures and 60 tables includes